Illumina (NASDAQ:ILMN) Director Keith Meister Sells 299,336 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 299,336 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the sale, the director directly owned 1,409,851 shares of the company’s stock, valued at $307,291,123.96. The trade was a 17.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Illumina Trading Up 2.9%

ILMN traded up $6.16 during midday trading on Friday, reaching $219.40. 1,917,079 shares of the company’s stock traded hands, compared to its average volume of 2,061,622. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $220.43. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a fifty day moving average of $188.01 and a two-hundred day moving average of $152.44. The stock has a market capitalization of $33.13 billion, a price-to-earnings ratio of 40.93, a P/E/G ratio of 3.00 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fiduciary Financial Advisors purchased a new stake in shares of Illumina in the 2nd quarter worth $26,000. Keating Financial Advisory Services Inc. bought a new stake in Illumina during the second quarter valued at about $32,000. Rakuten Securities Inc. purchased a new stake in Illumina in the second quarter worth about $33,000. Elyxium Wealth LLC purchased a new stake in Illumina in the fourth quarter worth about $25,000. Finally, TD Waterhouse Canada Inc. bought a new position in shares of Illumina in the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent research reports. Canaccord Genuity Group lifted their price target on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Stifel Nicolaus raised their target price on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Piper Sandler reissued an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Finally, Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.